Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
about
Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study.Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis.Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study.Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab.Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study throughPersistence with biologic agents for the treatment of rheumatoid arthritis in Japan.A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment.Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study.Correlation of Demographic and Clinical Characteristics with Rheumatoid Factor Seropositivity in Rheumatoid Arthritis Patients.Treatment with anti–tumor necrosis factor biologic agents in human T lymphotropic virus type I–positive patients with rheumatoid arthritis.Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J).Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients.Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.Efficacy and safety of reducing duration of infliximab infusion.Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis.Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia®as Biological Intensive Treatment for RA (ORBIT) study
P2860
Q34012929-C32D7C93-6255-4786-9A2E-9225331D406AQ34462435-D63FEBE1-E3EF-4AA2-9652-4532E446B0DBQ34462584-6BAA2ECC-2E5F-41E6-884C-55624E41C19DQ34656204-DB5F8829-B154-48E8-AC61-2D5BA7C73852Q35107327-8FDD3859-AC9A-447F-83F2-874A4B15721FQ35223223-2C751860-1811-49D5-995E-5BA13035DD95Q35610243-A39FB1C1-2853-4D3C-8FCB-FF0DC2A0B680Q35907845-E016BF95-6220-4124-A49F-1B276F551C01Q37130039-54D833D1-56EA-4E34-8835-FAC637A11908Q37167818-5603DC4F-7F13-43B0-A145-1B69EE0D0D7EQ37378732-0CBCF92D-5F95-4F2D-8209-4DB9351CD6CFQ37380288-CC3264CF-F373-4257-BB6A-F4C7CD70C027Q37530709-774A9C92-59D1-4EC5-A0D0-787403B10167Q42262404-F04DC852-2947-485B-992C-30E8EB89713BQ43269896-4685A2CB-5EDF-4D90-A746-802D2B4E11B5Q44650673-7E921B5A-9CF2-4BC4-B040-E95B4FEDCA5BQ45938776-114A1F1A-5ED2-4071-B41A-862F2CAAC7D8Q45939125-AD8F0329-C00F-4AA5-8480-C7255431ABE3Q48744497-897109C5-2FD6-4F17-82D6-8E5B27CEBEADQ49901596-180CACDE-A905-44E9-9836-606733EDE9F6Q50591145-4DE2002C-F6AC-404F-9EC6-D2B9FC1D1BCCQ54571843-7BAD7952-6EC4-4803-A8A9-8F5FE275D3E5Q55000881-4F4602E2-6D17-4DFF-BA49-9954EC193F08Q58204675-0EEE8033-B1F6-485F-AE9B-2AE45ECEA8EE
P2860
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Retrospective clinical study o ...... linical outcomes (RECONFIRM-2)
@ast
Retrospective clinical study o ...... linical outcomes (RECONFIRM-2)
@en
type
label
Retrospective clinical study o ...... linical outcomes (RECONFIRM-2)
@ast
Retrospective clinical study o ...... linical outcomes (RECONFIRM-2)
@en
prefLabel
Retrospective clinical study o ...... linical outcomes (RECONFIRM-2)
@ast
Retrospective clinical study o ...... linical outcomes (RECONFIRM-2)
@en
P2093
P2860
P1433
P1476
Retrospective clinical study o ...... linical outcomes (RECONFIRM-2)
@en
P2093
Eisuke Inoue
Hideto Kameda
Hisashi Yamanaka
Kazuyoshi Saito
Kouichi Amano
Masao Nawata
Naoya Sekiguchi
Shigeru Iwata
Tsutomu Takeuchi
P2860
P304
P356
10.3109/S10165-008-0026-3
P577
2008-02-19T00:00:00Z